English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

High-content screening: a new primary screening tool?

MPS-Authors
/persons/resource/persons219009

Bickle,  Marc
Max Planck Institute of Molecular Cell Biology and Genetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Bickle, M. (2008). High-content screening: a new primary screening tool? Idrugs, 11(11), 822-826.


Cite as: https://hdl.handle.net/21.11116/0000-0001-0E22-A
Abstract
Given a pharmaceutical landscape in which fewer drugs are succeeding in reaching the market, pharmaceutical and biotechnological companies are seeking alternative screening methodologies that will be compatible with the large scale of current combinatorial chemical libraries. In this context, HCS has received considerable attention. Imaging technologies are playing an increasing role in the drug discovery and development process, and this role is projected to increase further in the future. Currently, these technologies are rarely applied in primary screening campaigns but, rather, are used in the processes that precede and follow primary screening. Imaging technologies are employed for target identification and validation, secondary screening, ADMET studies, and pharmacokinetic studies. Various labeling technologies are deployed for such imaging, including fluorescence, luminescence, PET and computer tomography (CT). This feature review discusses high-content analysis (HCA), including the HCS technology and methodology involved, and the future potential of HCA in the drug discovery process.